VanEck Pharmaceutical ETF
142 hedge funds and large institutions have $516M invested in VanEck Pharmaceutical ETF in 2024 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 46 increasing their positions, 42 reducing their positions, and 27 closing their positions.
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
12.35% more ownership
Funds ownership: 75.6% → 87.95% (+12%)
10% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 42
0% more funds holding
Funds holding: 142 → 142 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less capital invested
Capital invested by funds: $545M → $516M (-$28.7M)
71% less call options, than puts
Call options by funds: $1.25M | Put options by funds: $4.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$17.6M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$17.5M |
| 3 |
JSAM
J. Safra Asset Management
New York
|
+$16.4M |
| 4 |
Two Sigma Investments
New York
|
+$13.1M |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$23.6M |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$14.5M |
| 3 |
FPGK
Financial Partners Group (Kansas)
Overland Park,
Kansas
|
-$8.82M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$7.4M |
| 5 |
BHB
Bank Hapoalim BM
Tel Aviv,
Israel
|
-$3.96M |
PPH Hedge Fund Activity: Q4 2024 in Review
142 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2024, worth a combined $516M — down 5.3% from $545M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PPH positions and 27 closed out — a net gain of 4 holders — while 46 added to existing stakes and 42 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $17.6M. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $23.6M sold.
- 142 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $516M of VanEck Pharmaceutical ETF stock for Q4 2024, down 5.3% quarter-over-quarter.
- 31 funds opened new VanEck Pharmaceutical ETF positions in Q4 2024 and 27 closed out, a net change of +4 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2024 was Goldman Sachs, an estimated $17.6M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2024 was Mirae Asset Global Investments, an estimated $23.6M sold.
Based on aggregated 13F filings for Q4 2024.